Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification
- 1 October 2014
- journal article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 17 (3) , 238-246
Abstract
In 2011, the St Gallen panel introduced several changes in breast cancer classification, thereby creating the luminal B Her2− subtype. In 2013, the panel also included Ki67 overexpression and PR p = 0.004, 0.005, and 0.007). Luminal A sub-type patients showed significantly less distant metastases than the rest, including luminal B Her2− patients (p < 0.001). Also, luminal B patients showed significantly less distant metastases than pure Her2 (0.05) and triple negative (TN) (p < 0.001). There were no differences between pure Her2 and TN patients (0.055), neither among the different luminal B sub-types. GH3, PR, and Ki67 may all be discriminatory factors for metastasis and specific mortality. Therefore, we suggest including GH3 in the luminal B subtype in the absence of Ki67.Keywords
This publication has 34 references indexed in Scilit:
- Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancerBMC Cancer, 2012
- Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial designThe Breast, 2012
- Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast CancerJNCI: Journal of the National Cancer Institute, 2011
- Luminal-B breast cancer and novel therapeutic targetsBreast Cancer Research, 2011
- High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or SmallerJournal of Clinical Oncology, 2009
- Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004The Breast Journal, 2009
- Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancerBreast Cancer Research and Treatment, 2008
- The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–2004Cancer, 2008
- Hormone receptor status and survival in a population‐based cohort of patients with breast carcinomaCancer, 2005
- Molecular portraits of human breast tumoursNature, 2000